
    
      This is a Open-label multicenter study to evaluate the ability of CGB-400 Gel to reduce
      facial redness and bumps/blemishes typically associated with rosacea. Approximately 25
      subjects will be enrolled.

      Subjects will receive study treatment for 12 weeks and attend a total of 5 study visits
      (i.e., BL, W2, W4, W8, W12).
    
  